Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to market. By combining generative artificial intelligence with high-throughput wet lab technologies, Absci aims to drastically cut down the time and cost associated
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early 2025, following pivotal statements from President Donald Trump regarding his administration's tariff policies. These sudden rallies underscore the profound sensitivity
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have staged a notable rebound. This split reaction, observed around October 12, 2025, highlights the immediate and often contrasting interpretations of heightened geopolitical risks and
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine a harsh light on persistent inflation. This report, due for release amidst an ongoing government shutdown, is
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This proactive announcement, made well in advance of the payment date, underscores the company's consistent commitment to shareholder
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This declaration, made on the current date of October 9, 2025, underscores the company's consistent commitment to shareholder
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been delayed indefinitely. This immediate consequence of the government's funding lapse creates a significant blind spot for
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
